Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: per strandberg who wrote (2728)	11/12/1997 7:36:00 PM
From: Oliver & Co	Read Replies (1) of 6136

Combination therapy with Invirase and Norvir has been largely published. But Saquinavir can actually be used in combo with many other drugs (except antagonistic with Cryx). One good combo is actually Viracept/SQV, since Nelf will increase SQV levels significantly. Re. life of Viracept, it should very strong in the US, for at least the next 3 years. The 141 product should not affect it when it is released probably mid-late next year. 1592 can be used in combo. I do not foresee any significant new drugs(UNFORTUNATELY) for the next 3-4 years. After that it will continue strong in other parts of the world. JLL

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next